OxLDL plasma levels in patients with Alzheimer's disease

被引:1
|
作者
Grossi, Marina Felipe [1 ]
Gracas Carvalho, Maria das [1 ]
Silveira, Josionne Nicacio [1 ]
Goncalves, Gisele Santos [1 ,2 ]
Gomes, Karina Braga [1 ]
Bicalho, Maria Aparecida [3 ,4 ]
Oliveira Silva, Ieda de Fatima [1 ]
机构
[1] Univ Fed Minas Gerais, Fac Farm, Dept Anal Clin & Toxicol, Belo Horizonte, MG, Brazil
[2] Ctr Univ Newton Paiva, Belo Horizonte, MG, Brazil
[3] Univ Fed Minas Gerais, Hosp Clin, Inst Jenny de Andrade Faria, Belo Horizonte, MG, Brazil
[4] Univ Fed Minas Gerais, Fac Med, Dept Clin Med, Belo Horizonte, MG, Brazil
关键词
Alzheimer's disease; Cholesterol; LDL; BRAZILIAN VERSION; DEMENTIA; VALIDITY; RELIABILITY; ASSOCIATION; CHOLESTEROL; OXIDATION; PROTEIN; RISK;
D O I
10.1590/0004-282X20180012
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: The objective of this study was to characterize the conventional lipid profile, oxLDL levels and ApoE polymorphism in patients with Alzheimer's disease (AD) and in elderly individuals without cognitive impairment. Methods: Eighty elderly individuals were selected and the levels of oxLDL were determined using the ELISA kit, and ApoE gene polymorphism was investigated using polymerase chain reaction-restriction fragment length polymorphism. Results: Significantly reduced levels of oxLDL were observed in patients with AD compared to the control group. A higher frequency of the ApoE epsilon 4 allele was observed in patients with AD compared to controls. No difference was observed for total cholesterol, HDL-C, and LDL-C levels between the two groups, while triglyceride levels were higher in controls compared with patients with AD. Conclusion: The data analyzed together did not reveal significant differences in lipid profiles, including oxLDL levels. However, the importance of lipid changes in the genesis of the disease cannot be ruled out. Nevertheless, the ApoE epsilon 4 allele was significantly more frequent in patients with Alzheimer's dementia in agreement with previous findings in the literature, but this genetic component did not change the levels of oxLDL.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 50 条
  • [21] Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease
    Lorenzl, S
    Albers, DS
    Relkin, N
    Ngyuen, T
    Hilgenberg, SL
    Chirichigno, J
    Cudkowicz, ME
    Beal, MF
    NEUROCHEMISTRY INTERNATIONAL, 2003, 43 (03) : 191 - 196
  • [22] DHEA-S plasma levels and incidence of Alzheimer's disease
    Hillen, T
    Lun, A
    Reischies, FM
    Borchelt, M
    Steinhagen-Thiessen, E
    Schaub, RT
    BIOLOGICAL PSYCHIATRY, 2000, 47 (02) : 161 - 163
  • [23] Plasma Resistin Levels in the Preclinical Stage of Alzheimer's Disease
    Eruysal, Emily
    Chen, Bandy
    Iadecola, Costantino
    Ishii, Makoto
    ANNALS OF NEUROLOGY, 2022, 92 : S57 - S58
  • [24] Plasma neurofilament light chain levels in Alzheimer's disease
    Zhou, Wenjun
    Zhang, Jie
    Ye, Fanlong
    Xu, Guangzheng
    Su, Hang
    Su, Yindan
    Zhang, Xiangyang
    NEUROSCIENCE LETTERS, 2017, 650 : 60 - 64
  • [25] Plasma Aβ levels are increased in Alzheimer's disease and decrease with progression
    Graff-Radford, NR
    Younkin, LH
    O'Brien, PC
    Younkin, SG
    NEUROLOGY, 2000, 54 (07) : A316 - A316
  • [26] Effect of rivastigmine on plasma butyrylcholine esterase activity and plasma ghrelin levels in patients with dementia in Alzheimer's disease
    Kuroda, Atsushi
    Setoguchi, Manabu
    Uchino, Yasushi
    Nagata, Kazuya
    Hokonohara, Daisuke
    GERIATRICS & GERONTOLOGY INTERNATIONAL, 2018, 18 (06) : 886 - 891
  • [27] Serum Lipid Levels in Patients with Alzheimer's Disease
    Presecki, Paola
    Mueck-Seler, Dorotea
    Mimica, Ninoslav
    Pivac, Nela
    Mustapic, Maja
    Stipcevic, Tamara
    Smalc, Vera Folnegovic
    COLLEGIUM ANTROPOLOGICUM, 2011, 35 : 115 - 120
  • [28] Lowering homocysteine levels in patients with Alzheimer's disease
    Aisen, P
    Sano, M
    Diaz-Arrastia, R
    Jagust, W
    DRUG DISCOVERY AND DEVELOPMENT FOR ALZHEIMER'S DISEASE, 2000, 2002, : 225 - 233
  • [29] Plasma Levels of Amyloid-β Peptides and Tau Protein in Mexican Patients with Alzheimer's Disease
    Castillo-Mendieta, Tzayaka
    Arana-Lechuga, Yoaly
    Campos-Pena, Victoria
    Luisa Sosa, Ana
    Orozco-Suarez, Sandra
    Pinto-Almazan, Rodolfo
    Segura-Uribe, Julia
    Rodriguez-Sanchez de Tagle, Aldo Javier
    Ruiz-Sanchez, Elizabeth
    Guerra-Araiza, Christian
    JOURNAL OF ALZHEIMERS DISEASE, 2021, 82 : S271 - S281
  • [30] Levels of autoantibodies to redox-modified abeta are attenuated in the plasma of Alzheimer's disease patients
    Moir, RD
    Tseitlin, KA
    Soscia, S
    Hyman, BT
    Irizarry, MC
    Tanzi, RE
    NEUROBIOLOGY OF AGING, 2004, 25 : S35 - S36